Thermo Fisher Scientific Past Earnings Performance
Past criteria checks 3/6
Thermo Fisher Scientific has been growing earnings at an average annual rate of 10.9%, while the Life Sciences industry saw earnings growing at 16.4% annually. Revenues have been growing at an average rate of 13.3% per year. Thermo Fisher Scientific's return on equity is 13.1%, and it has net margins of 14.2%.
Key information
10.9%
Earnings growth rate
11.6%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 13.3% |
| Return on equity | 13.1% |
| Net Margin | 14.2% |
| Last Earnings Update | 30 Mar 2024 |
Recent past performance updates
Recent updates
Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24
Thermo Fisher Scientific: Too Hot To Handle
Apr 15Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)
Apr 02We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Thermo Fisher's Bright Future Makes It A Great Buy On Weakness
Feb 06Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics
Jan 16Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'
Jan 06Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?
Dec 29Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 11Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.
Dec 02Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07My Family Is Buying A Lot More Thermo Fisher Stock
Oct 31Thermo Fisher: An Up To 35% Undervalued Healthcare Gem I Like On Weakness
Sep 28Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Sep 10Thermo Fisher Scientific: A High-Quality Investment For Double-Digit Returns
Aug 28Thermo Fisher: Cash Flow Returns On Investments Analysis
Aug 14Calculating The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 25Thermo Fisher Scientific: Continuing To Add To The Fortress
Jul 09Thermo Fisher: A Master Compounder In Healthcare
Jul 03These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Jun 07Buy Thermo Fisher, But With Caution
Jun 01Revenue & Expenses BreakdownBeta
How Thermo Fisher Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Mar 24 | 42,492 | 6,034 | 8,466 | 1,322 |
| 31 Dec 23 | 42,857 | 5,995 | 8,381 | 1,337 |
| 30 Sep 23 | 43,421 | 5,941 | 8,523 | 1,401 |
| 01 Jul 23 | 43,524 | 5,721 | 8,694 | 1,433 |
| 01 Apr 23 | 43,807 | 6,024 | 8,781 | 1,453 |
| 31 Dec 22 | 44,915 | 6,950 | 8,940 | 1,471 |
| 01 Oct 22 | 44,167 | 7,032 | 8,854 | 1,472 |
| 02 Jul 22 | 42,820 | 7,439 | 8,611 | 1,472 |
| 02 Apr 22 | 41,123 | 7,603 | 8,317 | 1,450 |
| 31 Dec 21 | 39,211 | 7,725 | 7,857 | 1,406 |
| 02 Oct 21 | 39,059 | 8,565 | 7,843 | 1,390 |
| 03 Jul 21 | 38,250 | 8,596 | 7,462 | 1,335 |
| 03 Apr 21 | 35,894 | 7,924 | 7,199 | 1,256 |
| 31 Dec 20 | 32,218 | 6,375 | 6,940 | 1,181 |
| 26 Sep 20 | 28,497 | 4,879 | 6,360 | 1,067 |
| 27 Jun 20 | 26,248 | 3,706 | 6,292 | 1,018 |
| 28 Mar 20 | 25,647 | 3,669 | 6,114 | 1,000 |
| 31 Dec 19 | 25,542 | 3,696 | 6,139 | 1,003 |
| 28 Sep 19 | 25,220 | 3,592 | 6,060 | 992 |
| 29 Jun 19 | 24,868 | 3,541 | 6,025 | 985 |
| 30 Mar 19 | 24,630 | 3,174 | 6,033 | 981 |
| 31 Dec 18 | 24,358 | 2,938 | 6,022 | 967 |
| 29 Sep 18 | 23,898 | 2,570 | 6,022 | 949 |
| 30 Jun 18 | 23,094 | 2,395 | 5,888 | 926 |
| 31 Mar 18 | 22,006 | 2,256 | 5,632 | 906 |
| 31 Dec 17 | 20,918 | 2,228 | 5,428 | 887 |
| 30 Sep 17 | 19,824 | 2,330 | 5,214 | 867 |
| 01 Jul 17 | 19,199 | 2,270 | 5,064 | 833 |
| 01 Apr 17 | 18,744 | 2,174 | 4,999 | 794 |
| 31 Dec 16 | 18,274 | 2,025 | 4,883 | 754 |
| 01 Oct 16 | 17,973 | 1,999 | 4,814 | 723 |
| 02 Jul 16 | 17,606 | 2,003 | 4,711 | 711 |
| 02 Apr 16 | 17,341 | 1,998 | 4,639 | 703 |
| 31 Dec 15 | 16,965 | 1,980 | 4,566 | 692 |
| 26 Sep 15 | 16,806 | 1,978 | 4,633 | 695 |
| 27 Jun 15 | 16,854 | 1,971 | 4,732 | 698 |
| 28 Mar 15 | 16,905 | 1,738 | 4,823 | 707 |
| 31 Dec 14 | 16,890 | 1,896 | 4,788 | 691 |
| 27 Sep 14 | 15,864 | 1,635 | 4,415 | 613 |
| 28 Jun 14 | 14,884 | 1,482 | 4,031 | 534 |
| 29 Mar 14 | 13,802 | 1,481 | 3,638 | 447 |
| 31 Dec 13 | 13,090 | 1,279 | 3,373 | 396 |
| 28 Sep 13 | 12,883 | 1,322 | 3,357 | 389 |
| 29 Jun 13 | 12,777 | 1,304 | 3,358 | 385 |
Quality Earnings: TMO has high quality earnings.
Growing Profit Margin: TMO's current net profit margins (14.2%) are higher than last year (13.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TMO's earnings have grown by 10.9% per year over the past 5 years.
Accelerating Growth: TMO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TMO had negative earnings growth (-0.2%) over the past year, making it difficult to compare to the Life Sciences industry average (-6.6%).
Return on Equity
High ROE: TMO's Return on Equity (13.1%) is considered low.